Trials / Terminated
TerminatedNCT04349280
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bintrafusp alfa | Participants will receive bintrafusp alfa. |
Timeline
- Start date
- 2020-10-15
- Primary completion
- 2022-08-15
- Completion
- 2022-08-15
- First posted
- 2020-04-16
- Last updated
- 2024-04-18
- Results posted
- 2024-04-18
Locations
12 sites across 5 countries: United States, Canada, France, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04349280. Inclusion in this directory is not an endorsement.